+0.37%
Today
Loading 1D prices…
Company profile
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New Jersey.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
PRINCETON, NJ, United States
Employees
54
Fiscal year end
1231
CIK
1699382
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| APLMApollomics Inc. Class A Ordinary Shares | $70.1M | $8.5M | -128.69% | -$52.80 | -4.81% | Unrated |
| SPROSpero Therapeutics Inc. Common Stock | $71.6M | $12.6M | +68.11% | $0.15 | -1.60% | Buy |
| CNTBConnect Biopharma Holdings Limited Ordinary Shares | $69M | $64K | -86687.50% | -$1.00 | -0.45% | Buy |
| ATHEAlterity Therapeutics Limited American Depositary Shares | $68.6M | — | — | -$1.33 | -2.65% | Buy |
| CINGCingulate Inc. Common Stock | $73.4M | $0.00 | — | -$4.44 | -4.55% | Buy |